Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date

被引:73
|
作者
Lee, Mary R. [1 ,2 ]
Rohn, Matthew C. H. [1 ,2 ]
Tanda, Gianluigi [3 ]
Leggio, Lorenzo [1 ,2 ,4 ]
机构
[1] NIAAA, Sect Clin Psychoneuroendocrinol & Neuropsychophar, 10 Ctr Dr,MSC 1108, Bethesda, MD 20892 USA
[2] NIDA, 10 Ctr Dr,MSC 1108, Bethesda, MD 20892 USA
[3] NIDA, Medicat Dev Program, Mol Targets & Medicat Discovery Branch, Baltimore, MD 20892 USA
[4] Brown Univ, Ctr Alcohol & Addict Studies, Dept Behav & Social Sci, Providence, RI 02912 USA
基金
美国国家卫生研究院;
关键词
CONDITIONED PLACE PREFERENCE; CHRONIC MORPHINE TREATMENT; COCAINE-SEEKING BEHAVIOR; MEDIAL PREFRONTAL CORTEX; PAIR BOND FORMATION; PROLYL-D-LEUCINE; INTRANASAL OXYTOCIN; NUCLEUS-ACCUMBENS; NEUROHYPOPHYSEAL HORMONES; SUBTHALAMIC NUCLEUS;
D O I
10.1007/s40263-016-0313-z
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The neuropeptide oxytocin plays a role in reward, stress, social affiliation, learning, and memory processes. As such, there is increasing interest in oxytocin as a potential treatment for addictions. The endogenous oxytocin system is itself altered by short- or long-term exposure to drugs of abuse. A large number of preclinical studies in rodents have investigated the effect of oxytocin administration on various drug-induced behaviors to determine whether oxytocin can reverse the neuroadaptations occurring with repeated drug and alcohol use. In addition, the mechanisms by which oxytocin acts to modify the behavioral response to drugs of abuse are beginning to be understood. More recently, a few small clinical studies have been conducted in cocaine, cannabis, and alcohol dependence. This review summarizes the preclinical as well as clinical literature to date on the oxytocin system and its relevance to drug and alcohol addiction.
引用
下载
收藏
页码:109 / 123
页数:15
相关论文
共 50 条
  • [41] Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date
    Fung, Lawrence K.
    Hardan, Antonio Y.
    CNS DRUGS, 2015, 29 (06) : 453 - 463
  • [42] Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date
    Lawrence K. Fung
    Antonio Y. Hardan
    CNS Drugs, 2015, 29 : 453 - 463
  • [43] REWARD SYSTEM DYSFUNCTION AS A PREDICTOR OF PSYCHOSIS AND ADDICTIVE DISORDERS
    Heinz, A.
    EUROPEAN PSYCHIATRY, 2013, 28
  • [44] Targeting the correct HDAC(s) to treat cognitive disorders
    Fischer, Andre
    Sananbenesi, Farahnaz
    Mungenast, Alison
    Tsai, Li-Huei
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2010, 31 (12) : 605 - 617
  • [45] Targeting glutamate uptake to treat alcohol use disorders
    Rao, P. S. S.
    Bell, Richard L.
    Engleman, Eric A.
    Sari, Youssef
    FRONTIERS IN NEUROSCIENCE, 2015, 9
  • [46] Targeting the Endocannabinoid System to Treat Sepsis
    Sardinha, Joel
    Lehmann, Christian
    Kelly, Melanie
    SIGNA VITAE, 2013, 8 (01) : 9 - 14
  • [47] Targeting the Oxytocin System: New Pharmacotherapeutic Approaches
    Gulliver, Damien
    Werry, Eryn
    Reekie, Tristan A.
    Katte, Timothy A.
    Jorgensen, William
    Kassiou, Michael
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2019, 40 (01) : 22 - 37
  • [48] Towards a Global Vaccine Safety Datalink: Rationale, Available Infrastructure Globally and Progress to Date
    Black, S. B.
    VACCINE, 2008,
  • [49] Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
    Verwey, Charl
    Dangor, Ziyaad
    Madhi, Shabir A.
    PEDIATRIC DRUGS, 2024, 26 (02) : 101 - 112
  • [50] Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
    Charl Verwey
    Ziyaad Dangor
    Shabir A. Madhi
    Pediatric Drugs, 2024, 26 : 101 - 112